Status:
UNKNOWN
Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy
Lead Sponsor:
Dalian University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
55-75 years
Phase:
PHASE1
Brief Summary
to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA
Eligibility Criteria
Inclusion
- TNM (tumor node metastasis ) staging with non distant metastasis; no other tumors
Exclusion
- having received previous treatment for liver cancer
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03235167
Start Date
October 1 2017
End Date
October 1 2022
Last Update
September 18 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.